Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2

  1. 824 Posts.
    lightbulb Created with Sketch. 44

    In 2019, Mesoblast Ltd  (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategy  


    http://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.61
Change
-0.010(0.62%)
Mkt cap ! $2.050B
Open High Low Value Volume
$1.61 $1.62 $1.57 $3.037M 1.906M

Buyers (Bids)

No. Vol. Price($)
22 40303 $1.61
 

Sellers (Offers)

Price($) Vol. No.
$1.61 35684 40
View Market Depth
Last trade - 12.36pm 08/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.